Chemotherapy, radiation, and immunotherapy before surgery for low rectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests combining standard chemotherapy and radiation with an immunotherapy drug (QL1706) before surgery for low rectal cancer. The goal is to see if this approach shrinks tumors more effectively and improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with rectal cancer that is low in the rectum (within about 7 cm from the opening).
- The cancer has not spread to other parts of the body.
- You are generally healthy and able to care for yourself (ECOG score 0-1).
- Your blood tests and organ function are within required limits.
- You are not pregnant, not breastfeeding, and willing to use contraception if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination treatment (enverolimab plus standard chemotherapy) given before surgery for very low rectal cancer. The goal is to shrink the tumor so much that patients may avoid surgery and keep their rectum, but the study is for those who haven't had treatment before.
This trial tests whether giving chemotherapy and an immunotherapy drug before surgery can help shrink rectal cancer tumors and improve outcomes. It is for patients whose tumors are not caused by a specific genetic mismatch repair problem.
This trial tests a new treatment sequence for locally advanced rectal cancer: a short course of radiation followed by a combination of immunotherapy (cadonilimab) and chemotherapy (mFOLFOX6) before surgery. The goal is to shrink the tumor more effectively and potentially improve outcomes.
This trial tests whether a short course of radiation before surgery, combined with the immunotherapy drug envafolimab and the chemo regimen CAPEOX, works better for shrinking locally advanced rectal cancer. It is aimed at people whose tumor is not “MMR-deficient” (it is pMMR/MSS), and it asks participants to be able to return for repeated checkups and treatments.
This trial tests a new combination of treatments (radiation, immunotherapy, and two chemotherapy drugs) given before surgery for people with a specific type of locally advanced rectal cancer that is close to the anus. The goal is to see if this approach is safe and effective.
This trial tests a combination of short-course radiation, chemotherapy (CapeOx), and an immunotherapy drug (PD-1 inhibitor) for people with early-stage rectal cancer who have had a local excision but are at high risk of the cancer coming back. The goal is to avoid more extensive surgery while still effectively treating the cancer.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.